- Home
- NRIX vs AAMI Comparison
NRIX vs AAMI Comparison
Compare NRIX & AAMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- AAMI
- Stock Information
- Founded
- NRIX 2009
- AAMI 1980
- Country
- NRIX United States
- AAMI United States
- Employees
- NRIX N/A
- AAMI N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- AAMI Investment Managers
- Sector
- NRIX Health Care
- AAMI Finance
- Exchange
- NRIX Nasdaq
- AAMI Nasdaq
- Market Cap
- NRIX 952.9M
- AAMI 1.1B
- IPO Year
- NRIX 2020
- AAMI N/A
- Fundamental
- Price
- NRIX $11.49
- AAMI $31.66
- Analyst Decision
- NRIX Strong Buy
- AAMI Hold
- Analyst Count
- NRIX 16
- AAMI 2
- Target Price
- NRIX $30.44
- AAMI $27.00
- AVG Volume (30 Days)
- NRIX 796.7K
- AAMI 205.3K
- Earning Date
- NRIX 07-10-2025
- AAMI 07-31-2025
- Dividend Yield
- NRIX N/A
- AAMI 0.13%
- EPS Growth
- NRIX N/A
- AAMI 46.05
- EPS
- NRIX N/A
- AAMI 2.40
- Revenue
- NRIX $56,417,000.00
- AAMI $519,799,999.00
- Revenue This Year
- NRIX $16.69
- AAMI $5.28
- Revenue Next Year
- NRIX N/A
- AAMI $6.24
- P/E Ratio
- NRIX N/A
- AAMI $13.10
- Revenue Growth
- NRIX N/A
- AAMI 18.00
- 52 Week Low
- NRIX $8.18
- AAMI $21.45
- 52 Week High
- NRIX $29.56
- AAMI $32.20
- Technical
- Relative Strength Index (RSI)
- NRIX 50.78
- AAMI N/A
- Support Level
- NRIX $12.25
- AAMI N/A
- Resistance Level
- NRIX $12.00
- AAMI N/A
- Average True Range (ATR)
- NRIX 0.69
- AAMI 0.00
- MACD
- NRIX -0.08
- AAMI 0.00
- Stochastic Oscillator
- NRIX 21.57
- AAMI 0.00
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About AAMI Acadian Asset Management Inc. Common Stock
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.